Skip to main content
. 2022 Apr 14;9(7):ofac203. doi: 10.1093/ofid/ofac203

Table 3.

Univariate Logistic Regression on Severe Adverse Reaction Resulting in Sick Leave After First and Second COVID-19 Vaccination in Fully Vaccinated Participants Without a History of SARS-CoV-2 Infection

Sick Leave After First Vaccinationa Sick Leave After Second Vaccinationa
Total (%) (n = 239) Crude OR (95% CI) Total (%) (n = 539) Crude OR (95% CI)
Age group
 15–29 y (reference) 72 (30.1) 1 155 (28.8) 1
 30–39 y 53 (22.2) 0.77 (0.53–1.13) 119 (22.1) 0.78 (0.59–1.03)
 40–49 y 50 (20.9) 0.72 (0.49–1.06) 129 (23.9) 0.86 (0.66–1.13)
 50–59 y 55 (23.0) 0.64 (0.44–0.93) 112 (20.8) 0.55 (0.42–0.73)
 60–69 y 9 (3.8) 0.33 (0.16–0.67) 24 (4.5) 0.36 (0.23–0.57)
Sex
 Male (reference) 47 (19.7) 1 120 (22.3) 1
 Female 191 (79.9) 1.69 (1.21–2.35) 419 (77.7) 1.50 (1.20–1.89)
 Divers 1 (0.4) 0
Occupational activity
 Nurse (reference) 71 (29.7) 1 193 (35.8) 1
 Physician 23 (9.6) 0.58 (0.36–0.95) 68 (12.6) 0.59 (0.43–0.80)
 Other occupation with direct patient contact 54 (22.6) 1.27 (0.87–1.85) 110 (20.4) 0.90 (0.69–1.18)
 Other occupation without direct patient contact 91 (38.1) 1.37 (0.99–1.91) 168 (31.2) 0.87 (0.68–1.10)
Vaccine
 BNT162b2 (reference) 51 (21.3) 1 408 (75.7) 1
 mRNA-1273 18 (7.5) 2.49 (1.43–4.34) 120 (22.3) 2.37 (1.83–3.06)
 ChAdOx1-S 167 (69.9) 28.94 (20.43–41.00) 11 (2.0) 0.38 (0.20–0.71)
 Ad26.COV2-S 3 (1.3) 32.24 (6.35–163.60)
BMI (n = 237/535) 1.00 (0.97–1.02) 0.98 (0.96–1.00)
Any chronic disease 58 (24.3) 1.13 (0.83–1.55) 135 (25.0) 1.22 (0.98–1.53)
Immunosuppression 7 (2.9) 1.19 (0.54–2.66) 13 (2.4) 0.94 (0.50–1.76)
Antipyretic medication before first vaccination 55 (23.0) 5.48 (3.83–7.84)
Antipyretic medication before second vaccination 43 (8.0) 1.09 (0.76–1.56)

Significant ORs (95% CI) are presented in bold.

Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

a

Percentages may not total 100 because of rounding.